コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia).
2 One patient died 13 days after TMVR from hospital-acquired pneumonia.
3 on use was associated with increased odds of hospital-acquired pneumonia.
4 an important cause of community-acquired and hospital-acquired pneumonia.
5 se was associated with 30% increased odds of hospital-acquired pneumonia.
6 mon pathogens associated with fatal cases of hospital-acquired pneumonia.
7 pportunistic pathogen and a leading cause of hospital-acquired pneumonia.
8 unity-acquired pneumonia and a rare cause of hospital-acquired pneumonia.
9 compared to those of their controls; 81% had hospital-acquired pneumonia, 13% had bloodstream infecti
10 monas aeruginosa is the most common cause of hospital-acquired pneumonia and a killer of immunocompro
11 ophylaxis may, however, increase the risk of hospital-acquired pneumonia and Clostridia difficile inf
13 gionnaires' disease is an important cause of hospital-acquired pneumonia and is caused by infection w
14 Staphylococcus aureus is a major cause of hospital-acquired pneumonia and is emerging as an import
15 icular, this bacterium is a leading cause of hospital-acquired pneumonia and is responsible for infec
16 Pseudomonas aeruginosa is a leading cause of hospital-acquired pneumonia, and approximately 80% of pa
17 ition, standardization of antibiotherapy for hospital-acquired pneumonia, and systematic approach to
18 um Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia, as a model for investigatin
19 ase 3 studies of telavancin for treatment of hospital-acquired pneumonia, cure rates for those with b
22 ppear to be at increased risk for death from hospital-acquired pneumonia, even after controlling for
23 fessionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associa
26 otyped S. aureus isolates from patients with hospital-acquired pneumonia (HAP) enrolled in two regist
27 o characterize the systemic host response in hospital-acquired pneumonia (HAP) when compared with com
29 tion between acid-suppressive medication and hospital-acquired pneumonia in patients with acute strok
31 able logistic regression, the adjusted OR of hospital-acquired pneumonia in the group exposed to acid
32 t Pseudomonas aeruginosa, a leading cause of hospital-acquired pneumonia, interferes with the ability
33 p in all patients with community-acquired or hospital-acquired pneumonias is a crucial measure for ma
34 s (eg, individuals with ventilator-requiring hospital-acquired pneumonia), it is imperative to kill >
35 cally significant gastrointestinal bleeding, hospital-acquired pneumonia, mortality, and the use of e
36 ication was ordered in 52% of admissions and hospital-acquired pneumonia occurred in 2219 admissions
37 ve medication was ordered in 1,340 (80%) and hospital-acquired pneumonia occurred in 289 (17.2%).
38 ceptor blockers did not increase the risk of hospital-acquired pneumonia (odds ratio 1.53; 95% confid
39 of P. aeruginosa isolates from patients with hospital-acquired pneumonia secreted type III proteins,
40 To determine the strategies of prevention of hospital-acquired pneumonia that reduce mortality in int
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。